US-based health-tech company Massive Bio has launched a new feature on its Patient Connect app, which integrates with the Oracle Cerner platform.
The new app feature aims to streamline access to electronic health records (EHRs) for cancer patients and healthcare providers.
It seeks to address the challenge of fragmented medical data in oncology, improving the enrollment process in clinical trials.
Massive Bio said the app supports its commitment to the Centres for Medicare & Medicaid Services (CMS) to boost healthcare interoperability in the US.
The new integration simplifies how patients access and compile their medical history.
Additionally, it allows the hospitals to address the difficulties in screening large populations for clinical trials, a significant operational challenge.
Massive Bio co-founder and CEO Selin Kurnaz said: “Our mission is to ensure that every cancer patient has access to the best possible treatment options, and that starts with breaking down data silos.
“By integrating with a leading EHR provider like Cerner, we are empowering patients to control their data and providing hospitals with the tools they need to accelerate life-saving research.
“This is a critical step forward in making clinical trial enrollment more efficient and equitable.”
Massive Bio said the partnership with Oracle Cerner provides significant access to the US healthcare system and enables better interoperability in the sector.
With Epic and Cerner covering most healthcare providers and hospital capacity, the partnership facilitates improved healthcare delivery and data management.
The application offers a dual solution, allowing patients to easily connect their My Cerner Chart to the Massive Bio profile.
It ensures that their medical data is readily available for analysis through Massive Bio’s advanced ASCO-featured AI pre-screening technologies.
The new app provides healthcare providers with a bulk data retrieval capability.
It allows hospitals and cancer centres using Cerner to effectively manage records of multiple patients who have consented.
The feature reduces the time and resources needed for clinical trial pre-screening, allowing research teams to identify trial candidates more effectively.
Massive Bio co-founder and chief medical AI officer Arturo Loaiza-Bonilla said: “For a patient, time is of the essence. The ability to instantly pull their medical history and match it against thousands of clinical trials can be a game-changer.
“For our hospital partners, the ability to run bulk data analysis means they can offer more trial opportunities to their patient populations, advancing cancer research and improving patient outcomes simultaneously.”
Last year, Massive Bio introduced a new free portal called Patient Connect to enable cancer patients to navigate their clinical trial journey from anywhere.
The platform will allow patients to find the appropriate clinical trial for them in the language of their choice after they provide access to their medical records.
